VV 261
Alternative Names: VV-261Latest Information Update: 20 Jan 2026
At a glance
- Originator Vigonvita Life Sciences
- Class Antivirals; Nucleotides
- Mechanism of Action RNA-dependent RNA polymerase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Severe fever with thrombocytopenia syndrome
Most Recent Events
- 16 Jan 2026 Pharmacodynamics data from preclinical studies in Severe fever with thrombocytopenia syndrome released by Vigonvita life Sciences (Vigonvita life Sciences pipeline, January 2026)
- 16 Jan 2026 Vigonvita Life Sciences plans a phase II trial for Severe fever with thrombocytopenia syndrome in the first half of 2027
- 04 Jan 2026 Phase-I clinical trials in Severe fever with thrombocytopenia syndrome (In volunteers) in China (PO) (CTR20254957) (NCT07302269)